PL403488A1 - Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina - Google Patents
Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulinaInfo
- Publication number
- PL403488A1 PL403488A1 PL403488A PL40348802A PL403488A1 PL 403488 A1 PL403488 A1 PL 403488A1 PL 403488 A PL403488 A PL 403488A PL 40348802 A PL40348802 A PL 40348802A PL 403488 A1 PL403488 A1 PL 403488A1
- Authority
- PL
- Poland
- Prior art keywords
- fusion protein
- taci
- immunoglobulin
- nucleic acid
- producing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
Abstract
Niniejszy wynalazek dotyczy zastosowania bialka fuzyjnego (TACI)-immunoglobulina do wytwarzania leku do leczenia wielu zaburzen lub chorób w których posrednicza receptory cytokinowe. Wynalazek dotyczy równiez bialka fuzyjnego TACI-immunoglobulina, czasteczki kwasu nukleinowego kodujacego to bialko, kompozycji farmaceutycznej i sposobu wytwarzania bialka fuzyjnego (TAGI)-immunoglobulina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29334301P | 2001-05-24 | 2001-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL403488A1 true PL403488A1 (pl) | 2013-07-08 |
Family
ID=23128690
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL366760A PL219013B1 (pl) | 2001-05-24 | 2002-05-20 | Białko fuzyjne TACI-immunoglobulina, kodująca je cząsteczka kwasu nukleinowego, sposób wytwarzania białka fuzyjnego TACI-immunoglobulina, zastosowanie białka fuzyjnego TACI-immunoglobulina i kompozycja farmaceutyczna zawierająca te białko fuzyjne |
PL403488A PL403488A1 (pl) | 2001-05-24 | 2002-05-20 | Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL366760A PL219013B1 (pl) | 2001-05-24 | 2002-05-20 | Białko fuzyjne TACI-immunoglobulina, kodująca je cząsteczka kwasu nukleinowego, sposób wytwarzania białka fuzyjnego TACI-immunoglobulina, zastosowanie białka fuzyjnego TACI-immunoglobulina i kompozycja farmaceutyczna zawierająca te białko fuzyjne |
Country Status (28)
Country | Link |
---|---|
US (9) | US20030103986A1 (pl) |
EP (2) | EP1436003B3 (pl) |
JP (2) | JP2004535182A (pl) |
KR (3) | KR101021124B1 (pl) |
CN (2) | CN1612750B (pl) |
AT (2) | ATE542545T1 (pl) |
AU (1) | AU2002305646C1 (pl) |
BR (1) | BRPI0209933B8 (pl) |
CA (1) | CA2448123C (pl) |
CY (2) | CY1109751T1 (pl) |
DE (1) | DE60234202D1 (pl) |
DK (2) | DK2116259T3 (pl) |
EA (2) | EA007275B1 (pl) |
ES (2) | ES2379977T3 (pl) |
HK (2) | HK1076603A1 (pl) |
HR (2) | HRP20030948B1 (pl) |
IL (2) | IL158920A0 (pl) |
ME (1) | MEP21708A (pl) |
MX (1) | MXPA03010687A (pl) |
NO (1) | NO337295B1 (pl) |
NZ (1) | NZ529638A (pl) |
PL (2) | PL219013B1 (pl) |
PT (2) | PT2116259E (pl) |
RS (2) | RS20120253A1 (pl) |
SI (2) | SI2116259T1 (pl) |
UA (1) | UA82830C2 (pl) |
WO (1) | WO2002094852A2 (pl) |
ZA (1) | ZA200308984B (pl) |
Families Citing this family (197)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US7833529B1 (en) * | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
US6969519B2 (en) | 2000-03-10 | 2005-11-29 | Human Genome Sciences, Inc. | Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17) |
ES2609016T3 (es) | 2000-06-16 | 2017-04-18 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a BLyS |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
EP2267019A3 (en) | 2000-08-18 | 2011-07-06 | Human Genome Sciences, Inc. | Binding polypeptides for B lymphocyte stimulator protein (BLyS) |
EA007275B1 (ru) | 2001-05-24 | 2006-08-25 | Займодженетикс, Инк. | Слитые белки taci-иммуноглобулина |
JP2004537290A (ja) | 2001-05-24 | 2004-12-16 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 腫瘍壊死因子δ(APRIL)に対する抗体 |
BR0211614A (pt) * | 2001-08-03 | 2006-10-31 | Genentech Inc | polipeptìdeo tacis e br3 e empregos dos mesmos |
US7112410B1 (en) | 2001-08-29 | 2006-09-26 | Human Genome Sciences, Inc. | Human tumor necrosis factor TR21 and methods based thereon |
WO2003024991A2 (en) * | 2001-09-21 | 2003-03-27 | Amgen Inc. | Tall-1 receptor molecules and uses thereof |
EP1495055B1 (en) * | 2002-04-18 | 2013-08-14 | Genencor International, Inc. | Production of functional antibodies in filamentous fungi |
AU2003267967B2 (en) * | 2002-06-18 | 2008-11-20 | Zymogenetics, Inc. | Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter |
EP1558278B1 (en) * | 2002-10-11 | 2009-09-02 | ZymoGenetics, Inc. | Production of homotrimeric fusion proteins |
EP3120861B1 (en) | 2003-11-06 | 2018-08-15 | Seattle Genetics, Inc. | Intermediate for conjugate preparation comprising auristatin derivatives and a linker |
EP1732946B1 (en) | 2004-03-08 | 2011-07-27 | ZymoGenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
CN102973947A (zh) | 2004-06-01 | 2013-03-20 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
ES2426005T3 (es) | 2004-07-23 | 2013-10-18 | Acceleron Pharma Inc. | Polipéptidos del receptor ACTRII, procedimientos y composiciones |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
NZ565511A (en) * | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
AU2006278227B2 (en) * | 2005-08-09 | 2011-10-20 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
CA2618765A1 (en) | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for treating b-cell malignancies using taci-ig fusion molecule |
AU2006281978A1 (en) * | 2005-08-12 | 2007-02-22 | Garvan Institute Of Medical Research | Phrophylactic and/or therapeutic method for treatment of autoimmune disease |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
AU2006344395B2 (en) | 2005-10-13 | 2013-05-02 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
KR20180030264A (ko) | 2005-11-23 | 2018-03-21 | 악셀레론 파마 인코포레이티드 | 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
JP2009525765A (ja) * | 2006-02-10 | 2009-07-16 | ザイモジェネティクス, インコーポレイテッド | 切断型のil−17ra可溶性受容体および炎症において使用する方法 |
WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
KR20090016707A (ko) * | 2006-05-15 | 2009-02-17 | 아레스 트레이딩 에스.에이. | Taciig 융합 분자를 사용하여 자가면역 질병을 치료하는 방법 |
CA2661936A1 (en) * | 2006-08-25 | 2008-02-28 | Margaret D. Moore | Soluble il-27 receptor |
NZ574626A (en) * | 2006-08-28 | 2011-12-22 | Ares Trading Sa | Process for removing free Fc-moieties from fluids comprising Fc-containing proteins using ion exchange chromatography |
JP2010501622A (ja) * | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Fc−融合タンパク質の精製法 |
NZ574623A (en) * | 2006-08-28 | 2011-12-22 | Ares Trading Sa | Process for the purification of fc-fusion proteins |
DK2061803T4 (da) * | 2006-08-28 | 2022-12-05 | Ares Trading Sa | Fremgangsmåde til oprensning af fc-holdige proteiner |
ATE531727T1 (de) | 2006-09-18 | 2011-11-15 | Compugen Ltd | Bioaktive peptide und verfahren zu ihrer verwendung |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
JP2010516744A (ja) | 2007-01-26 | 2010-05-20 | メルク セローノ ソシエテ アノニム | 油体技術を用いたFc−融合タンパク質の精製 |
RU2473362C2 (ru) | 2007-02-01 | 2013-01-27 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
EA018221B1 (ru) | 2007-02-09 | 2013-06-28 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
AU2008232311A1 (en) * | 2007-03-27 | 2008-10-02 | Niall Corcoran | Methods and compositions for treating prostate cancer |
PL2139517T3 (pl) | 2007-03-27 | 2013-10-31 | Zymogenetics Inc | Kombinacja hamowania BLyS i mykofenolanu mofetylu do leczenia choroby autoimmunologicznej |
CN101323643B (zh) * | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
US8415455B2 (en) | 2007-09-04 | 2013-04-09 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
EP2200631A1 (en) * | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
PT2219675E (pt) * | 2007-11-12 | 2013-11-18 | Ares Trading Sa | Formulações para proteínas de fusão de taci-imunoglobulina |
WO2009062916A1 (en) * | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of optic neuritis |
CA2705435A1 (en) * | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
KR101615215B1 (ko) | 2007-12-07 | 2016-04-25 | 지모제넥틱스, 인코포레이티드 | 항-사람 il-21 단클론성 항체 |
WO2009093246A2 (en) * | 2008-01-22 | 2009-07-30 | Compugen Ltd. | Novel clusterin derived peptide |
AU2009239437B2 (en) | 2008-04-25 | 2014-11-13 | University Of Washington | Levels of BCMA protein expression on B cells and use in diagnostic methods |
US8003335B2 (en) | 2008-04-30 | 2011-08-23 | Universite Paris-SUD11 | Levels of APRIL in serum and use in diagnostic methods |
HUE028784T2 (en) | 2008-05-01 | 2017-01-30 | Zymogenetics Inc | Serum levels and use of BLYS / APRIL heterotrimers in diagnostic procedures |
EP2313105B1 (en) | 2008-06-27 | 2013-07-24 | ZymoGenetics, Inc. | SOLUBLE HYBRID Fc gamma RECEPTORS AND RELATED METHODS |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
DK3494986T3 (da) | 2008-08-14 | 2020-08-03 | Acceleron Pharma Inc | GDF fanger |
WO2010038756A1 (ja) * | 2008-09-30 | 2010-04-08 | 協和発酵キリン株式会社 | Frizzled1、Frizzled2又はFrizzled7細胞外システインリッチドメインを含む蛋白質を含有する骨疾患治療用医薬組成物 |
WO2010067308A2 (en) | 2008-12-08 | 2010-06-17 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9238878B2 (en) * | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
CN107970445B (zh) | 2009-03-30 | 2021-09-07 | 阿塞勒隆制药公司 | Bmp-alk3拮抗剂和促进骨生长的用途 |
EP3845239A1 (en) | 2009-06-08 | 2021-07-07 | Acceleron Pharma Inc. | Use of anti-actriib proteins for increasing thermogenic adipocytes |
CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
PT2498799T (pt) | 2009-11-13 | 2016-11-04 | Five Prime Therapeutics Inc | Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2 |
AU2010322011B2 (en) | 2009-11-17 | 2016-03-31 | Acceleron Pharma Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
WO2011067711A2 (en) | 2009-12-01 | 2011-06-09 | Compugen Ltd | Novel heparanase splice variant |
WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
MX342017B (es) | 2010-03-26 | 2016-09-09 | Dartmouth College | Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos. |
BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
CN101851278B (zh) * | 2010-05-26 | 2013-03-13 | 石药集团中奇制药技术(石家庄)有限公司 | B细胞激活因子拮抗剂及其制备方法与用途 |
AU2011265054B2 (en) | 2010-06-08 | 2016-09-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CA2802017A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
EP3327035A1 (en) | 2010-06-22 | 2018-05-30 | Precision Biologics Inc. | Colon and pancreas cancer specific antigens and antibodies |
CN107441480A (zh) | 2010-06-30 | 2017-12-08 | 卡姆普根有限公司 | 多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途 |
EP2622091B1 (en) | 2010-09-23 | 2019-03-13 | Precision Biologics, Inc. | Colon and pancreas cancer peptidomimetics |
US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
WO2012090150A2 (en) | 2010-12-27 | 2012-07-05 | Compugen Ltd | New cell-penetrating peptides and uses thereof |
KR20140016262A (ko) | 2011-01-14 | 2014-02-07 | 레드우드 바이오사이언스 인코포레이티드 | 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법 |
CN102085367B (zh) * | 2011-01-19 | 2012-08-22 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用 |
CN105601741A (zh) | 2011-04-15 | 2016-05-25 | 卡姆普根有限公司 | 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途 |
MX2013013054A (es) | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
JP6342325B2 (ja) | 2011-05-25 | 2018-06-13 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 炎症性障害の治療のための抗kir抗体 |
AU2012277376B2 (en) | 2011-06-30 | 2016-11-24 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
CN103987407B (zh) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其偶联物 |
CN104168915A (zh) | 2011-11-14 | 2014-11-26 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
KR20140126357A (ko) | 2012-02-01 | 2014-10-30 | 컴퓨젠 엘티디. | C1orf32 항체 및 이의 암 치료를 위한 용도 |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
FI3421486T3 (fi) | 2012-06-22 | 2023-12-15 | Dartmouth College | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
JP6368308B2 (ja) | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | 癌の診断および治療のためのvista調節剤 |
NZ707490A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
CA2887894C (en) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
ES2660029T3 (es) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Conjugados de anticuerpo-pirrolobenzodiazepinas |
PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
PL2906298T3 (pl) | 2012-10-12 | 2019-04-30 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina - przeciwciało |
NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
CN103833856B (zh) * | 2012-11-22 | 2017-05-03 | 上海康岱生物医药技术股份有限公司 | 抑制taci‑baff复合物形成的融合蛋白及其制法和用途 |
ES2658888T5 (es) | 2012-12-21 | 2021-10-19 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
AU2013366490B9 (en) | 2012-12-21 | 2018-02-01 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
TWI680766B (zh) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
MX364330B (es) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
EP3033111B1 (en) | 2013-08-12 | 2019-03-13 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
PE20161394A1 (es) | 2013-12-16 | 2017-01-06 | Genentech Inc | Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco |
WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
BR112016013258A2 (pt) | 2013-12-16 | 2018-01-16 | Genentech Inc | composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
DK3712174T3 (da) | 2013-12-24 | 2022-04-25 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
EP3154585B1 (en) | 2014-06-11 | 2022-02-23 | Kathy A. Green | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
EP3154566B1 (en) | 2014-06-13 | 2022-08-03 | Acceleron Pharma Inc. | Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia |
US20170275344A1 (en) | 2014-08-26 | 2017-09-28 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of autoimmune disorders |
JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
SG11201702079UA (en) | 2014-09-17 | 2017-04-27 | Genentech Inc | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
ES2749716T3 (es) | 2014-10-28 | 2020-03-23 | Merck Patent Gmbh | Métodos de despliegue de proteínas que contienen dominios Fc no covalentes sobre la superficie de células y métodos de selección de las mismas |
WO2016070959A1 (en) | 2014-11-03 | 2016-05-12 | Merck Patent Gmbh | Methods for generating bispecific shark variable antibody domains and use thereof |
MX2017006770A (es) | 2014-11-25 | 2018-02-09 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepina y anticuerpo. |
JP6752204B2 (ja) | 2014-12-03 | 2020-09-09 | ジェネンテック, インコーポレイテッド | 四級アミン化合物及びその抗体−薬物コンジュゲート |
EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
MX2017007136A (es) | 2014-12-05 | 2017-12-04 | Immunext Inc | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
EP3331904B1 (en) | 2015-08-07 | 2020-12-23 | Merck Patent GmbH | A transglutamine tag for efficient site-specific bioconjugation |
WO2017044424A1 (en) | 2015-09-08 | 2017-03-16 | Theripion, Inc. | Apoa-1 fusion polypeptides and related compositions and methods |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN109069626A (zh) | 2016-02-12 | 2018-12-21 | 詹森药业有限公司 | 抗-vista(b7h5)抗体 |
US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
EP3426686A4 (en) | 2016-04-15 | 2019-11-06 | Alder Biopharmaceuticals, Inc. | HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF |
BR112018071153A2 (pt) | 2016-04-15 | 2019-04-16 | Immunext, Inc. | anticorpos anti-vista humano e uso dos mesmos |
WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
EP3494141A4 (en) | 2016-08-03 | 2020-04-08 | Bio-Techne Corporation | IDENTIFICATION OF VSIG3 / VISTA AS A NEW IMMUNE CONTROL POINT AND ITS USE IN IMMUNOTHERAPY |
JP7093767B2 (ja) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
WO2018136163A2 (en) | 2016-12-09 | 2018-07-26 | Theripion, Inc. | Tandem apoa-1 fusion polypeptides |
DK3544636T3 (da) | 2017-02-08 | 2021-05-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepin-antistof-konjugater |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
CN110582505B (zh) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
KR20200004325A (ko) | 2017-05-09 | 2020-01-13 | 사이아노 바이오테크 게엠베하 | 변형된 마이크로시스틴 및 노둘라린 |
WO2018219619A1 (en) | 2017-05-09 | 2018-12-06 | Cyano Biotech Gmbh | Method for modifying microcystins and nodularins |
AU2018285562B2 (en) | 2017-06-14 | 2024-01-18 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
RS62928B1 (sr) | 2017-08-18 | 2022-03-31 | Medimmune Ltd | Konjugati pirolobenzodiazepina |
IL273387B2 (en) | 2017-09-20 | 2023-10-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
JP2021512120A (ja) | 2018-02-02 | 2021-05-13 | バイオ−テクネ コーポレーション | Vistaとvsig3との相互作用を調節する化合物ならびにその製造および使用方法 |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
EP3870235A1 (en) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Conjugated chemical inducers of degradation and methods of use |
JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
US20220306734A1 (en) | 2019-07-24 | 2022-09-29 | H. Lundbeck A/S | Anti-mglur5 antibodies and uses thereof |
KR20220034742A (ko) * | 2019-12-24 | 2022-03-18 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질 및 그 용도 |
PE20230494A1 (es) | 2020-05-08 | 2023-03-23 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas |
IL298643A (en) * | 2020-06-02 | 2023-01-01 | Ares Trading Sa | Methods related to the treatment of iga nephropathy |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
EP4294916A2 (en) | 2021-02-19 | 2023-12-27 | Theripion, Inc. | Dnase fusion polypeptides and related compositions and methods |
CA3217586A1 (en) | 2021-05-07 | 2022-11-10 | Eliezer Katz | Use of an anti-cd19 antibody to treat myasthenia gravis |
IL308336A (en) | 2021-05-07 | 2024-01-01 | Alpine Immune Sciences Inc | Methods of dosing and treatment with TACI-FC modulatory fusion protein |
KR20240014066A (ko) * | 2021-09-30 | 2024-01-31 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질을 사용하여 쇼그렌 증후군을 치료하는 방법 |
WO2023051798A1 (zh) * | 2021-09-30 | 2023-04-06 | 江苏恒瑞医药股份有限公司 | 抗il23抗体融合蛋白及用途 |
WO2023236967A1 (zh) * | 2022-06-08 | 2023-12-14 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗重症肌无力的方法 |
WO2024067756A1 (zh) * | 2022-09-30 | 2024-04-04 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗膜性肾病的方法 |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US846A (en) | 1838-07-17 | Improvement in revolving fire-arms | ||
US5738A (en) | 1848-08-29 | Francis kelsey | ||
AU560472B2 (en) | 1981-08-25 | 1987-04-09 | Celltech Limited | Yeast expression vectors |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US4859587A (en) | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
DE3578435D1 (de) | 1984-12-06 | 1990-08-02 | Labofina Sa | Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden. |
US4751181A (en) | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
US5861151A (en) * | 1991-12-20 | 1999-01-19 | Bristol-Myers Squibb Co | Soluble fusion molecules with binding specificity for cell adhesion molecules |
ZA932522B (en) * | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
ZA932523B (en) * | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
WO1994009137A1 (en) | 1992-10-15 | 1994-04-28 | Genentech, Inc. | Antibodies against type 2 tumor necrosis factor receptor |
US5650550A (en) | 1993-10-01 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant mice having a deficit of functional estrogen receptors |
US5523227A (en) | 1994-06-17 | 1996-06-04 | The Board Of Trustees Of The Leland Stanford Junior Univ. | DNA encoding calcium-signal modulating cyclophilin ligand |
DK0871645T3 (da) | 1994-12-15 | 2007-12-03 | Yeda Res & Dev | Modulationer af FAS/APO1-receptorers funktion |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
DE19533447C1 (de) | 1995-09-09 | 1996-12-05 | Bbs Kraftfahrzeugtechnik | Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze |
US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
AU1158297A (en) | 1995-11-09 | 1997-05-29 | Zymogenetics Inc. | Production of gad65 in methylotrophic yeast |
ATE254135T1 (de) | 1996-03-14 | 2003-11-15 | Human Genome Sciences Inc | Humaner tumornekrosefaktor delta und epsilon |
AU718510B2 (en) | 1996-07-17 | 2000-04-13 | Zymogenetics Inc. | Transformation of pichia methanolica |
US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
CA2261020C (en) | 1996-07-17 | 2004-06-08 | Zymogenetics, Inc. | Preparation of pichia methanolica auxotrophic mutants |
DK0939804T4 (da) | 1996-10-25 | 2011-07-18 | Human Genome Sciences Inc | Neutrokin-alpha |
WO1998027114A2 (en) | 1996-12-17 | 1998-06-25 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
EP0975771B1 (en) * | 1997-04-18 | 2007-07-11 | Biogen Idec MA Inc. | Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins |
WO1998055620A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
CA2292835A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
AU9013998A (en) * | 1997-07-21 | 1999-02-10 | Zymogenetics Inc. | Tumor necrosis factor receptor ztnfr-5 |
AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
CZ294615B6 (cs) | 1997-09-12 | 2005-02-16 | Apotech R & D Sa | Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny |
NZ512753A (en) * | 1999-01-07 | 2003-10-31 | Zymogenetics Inc | Soluble receptor BR43x2 related proteins useful for inhibiting ztnf4 |
US20060067933A1 (en) * | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
HUP0105283A3 (en) | 1999-01-25 | 2004-08-30 | Biogen Idec Ma Inc Cambridge | Baff, inhibitors thereof and their use in the modulation of b-cell response |
WO2000062790A2 (en) | 1999-04-19 | 2000-10-26 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
PL211786B1 (pl) | 1999-08-17 | 2012-06-29 | Apoxis Sa | Zastosowanie przeciwciała oraz polipeptydu |
EP1218411A4 (en) * | 1999-09-20 | 2004-09-01 | Millennium Pharm Inc | SECRETED PROTEINS AND THEIR USES |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
ATE511857T1 (de) | 2000-02-16 | 2011-06-15 | Genentech Inc | Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
CA2404945C (en) * | 2000-04-27 | 2010-02-09 | Biogen, Inc. | Taci as an anti-tumor agent |
US20020086018A1 (en) | 2000-05-12 | 2002-07-04 | Theill Lars Eyde | Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI |
KR100886276B1 (ko) | 2000-08-11 | 2009-03-04 | 기린 파마 가부시끼가이샤 | 인산 대사, 칼슘 대사, 석회화 및 비타민 d 대사를조절하는 폴리펩티드 및 그것을 코딩하는 dna |
CA2428242A1 (en) | 2000-11-07 | 2002-05-16 | Zymogenetics, Inc. | Human tumor necrosis factor receptor |
AU2002238052A1 (en) | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
EA007275B1 (ru) * | 2001-05-24 | 2006-08-25 | Займодженетикс, Инк. | Слитые белки taci-иммуноглобулина |
PT2219675E (pt) | 2007-11-12 | 2013-11-18 | Ares Trading Sa | Formulações para proteínas de fusão de taci-imunoglobulina |
-
2002
- 2002-05-20 EA EA200301146A patent/EA007275B1/ru not_active IP Right Cessation
- 2002-05-20 CN CN02812698XA patent/CN1612750B/zh not_active Expired - Lifetime
- 2002-05-20 ES ES09168970T patent/ES2379977T3/es not_active Expired - Lifetime
- 2002-05-20 DE DE60234202T patent/DE60234202D1/de not_active Expired - Lifetime
- 2002-05-20 RS RS20120253A patent/RS20120253A1/en unknown
- 2002-05-20 AT AT09168970T patent/ATE542545T1/de active
- 2002-05-20 PL PL366760A patent/PL219013B1/pl not_active IP Right Cessation
- 2002-05-20 KR KR1020107010485A patent/KR101021124B1/ko active IP Right Grant
- 2002-05-20 US US10/152,363 patent/US20030103986A1/en not_active Abandoned
- 2002-05-20 CA CA2448123A patent/CA2448123C/en not_active Expired - Lifetime
- 2002-05-20 PT PT09168970T patent/PT2116259E/pt unknown
- 2002-05-20 SI SI200230979T patent/SI2116259T1/sl unknown
- 2002-05-20 NZ NZ529638A patent/NZ529638A/en not_active IP Right Cessation
- 2002-05-20 MX MXPA03010687A patent/MXPA03010687A/es active IP Right Grant
- 2002-05-20 IL IL15892002A patent/IL158920A0/xx active IP Right Grant
- 2002-05-20 DK DK09168970.3T patent/DK2116259T3/da active
- 2002-05-20 PL PL403488A patent/PL403488A1/pl not_active Application Discontinuation
- 2002-05-20 CN CN200910146212XA patent/CN101628111B/zh not_active Expired - Lifetime
- 2002-05-20 AU AU2002305646A patent/AU2002305646C1/en not_active Expired
- 2002-05-20 ES ES02734478T patent/ES2334772T7/es active Active
- 2002-05-20 RS YU92503A patent/RS52228B/en unknown
- 2002-05-20 KR KR1020097013141A patent/KR100976743B1/ko active IP Right Grant
- 2002-05-20 AT AT02734478T patent/ATE446771T1/de active
- 2002-05-20 BR BRPI0209933-0 patent/BRPI0209933B8/pt not_active IP Right Cessation
- 2002-05-20 PT PT02734478T patent/PT1436003E/pt unknown
- 2002-05-20 EP EP02734478A patent/EP1436003B3/en not_active Expired - Lifetime
- 2002-05-20 DK DK02734478.7T patent/DK1436003T3/da active
- 2002-05-20 WO PCT/US2002/015910 patent/WO2002094852A2/en active Application Filing
- 2002-05-20 EP EP09168970A patent/EP2116259B1/en not_active Expired - Lifetime
- 2002-05-20 SI SI200230868T patent/SI1436003T1/sl unknown
- 2002-05-20 JP JP2002592326A patent/JP2004535182A/ja not_active Withdrawn
- 2002-05-20 EA EA200600894A patent/EA010594B1/ru not_active IP Right Cessation
- 2002-05-20 KR KR10-2003-7015353A patent/KR20040030628A/ko not_active Application Discontinuation
- 2002-05-20 UA UA20031110605A patent/UA82830C2/uk unknown
- 2002-05-20 ME MEP-217/08A patent/MEP21708A/xx unknown
-
2003
- 2003-11-19 ZA ZA200308984A patent/ZA200308984B/en unknown
- 2003-11-20 HR HRP20030948AA patent/HRP20030948B1/hr not_active IP Right Cessation
- 2003-11-21 NO NO20035173A patent/NO337295B1/no not_active IP Right Cessation
-
2005
- 2005-09-29 HK HK05108608.2A patent/HK1076603A1/xx not_active IP Right Cessation
- 2005-10-03 US US11/242,294 patent/US7501497B2/en not_active Expired - Lifetime
-
2009
- 2009-01-26 US US12/359,801 patent/US7635767B2/en not_active Expired - Lifetime
- 2009-06-22 JP JP2009147774A patent/JP5149245B2/ja not_active Expired - Lifetime
- 2009-10-26 US US12/605,561 patent/US7964711B2/en not_active Expired - Fee Related
- 2009-11-04 US US12/612,288 patent/US7951919B2/en not_active Expired - Fee Related
- 2009-11-05 US US12/613,039 patent/US7862814B2/en not_active Expired - Fee Related
-
2010
- 2010-01-27 CY CY20101100079T patent/CY1109751T1/el unknown
- 2010-03-19 HK HK10102899.6A patent/HK1137659A1/xx not_active IP Right Cessation
-
2011
- 2011-05-11 US US13/105,182 patent/US8524232B2/en not_active Expired - Lifetime
- 2011-12-29 IL IL217265A patent/IL217265A/en active IP Right Grant
-
2012
- 2012-04-24 CY CY20121100381T patent/CY1112840T1/el unknown
-
2013
- 2013-05-09 HR HRP20130413AA patent/HRP20130413A2/hr not_active Application Discontinuation
- 2013-08-01 US US13/956,499 patent/US8815238B2/en not_active Expired - Lifetime
-
2014
- 2014-07-15 US US14/331,567 patent/US9346878B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL403488A1 (pl) | Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina | |
WO2002066516A3 (en) | Antibodies that bind both bcma and taci | |
AU3988401A (en) | Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins | |
HK1080511A1 (en) | Il-1 receptor based antagonists and methods of making and using | |
IL184761A0 (en) | Chromatographic media | |
WO2005017205A3 (en) | Nucleic acid mapping using linear analysis | |
WO2005047850A3 (en) | Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins | |
EE04783B1 (et) | TNF retseptoriga seotud faktori (TRAF) modulaatorid, nende valmistamine ja kasutamine | |
PL1622929T3 (pl) | Peptydy wiążące się z receptorem APO2L(TRAIL) oraz ich zastosowanie | |
WO2002101072A3 (en) | Letm1: modulators of cellular proliferation | |
EP1377826A4 (en) | opiate receptors | |
EP1568770A3 (en) | Pharmaceutical use of compounds which bind to a mammalian trace amine receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |